ATE500839T1 - Verfahren und verbindungen zur unterdrückung der fibrocyten-differenzierung - Google Patents
Verfahren und verbindungen zur unterdrückung der fibrocyten-differenzierungInfo
- Publication number
- ATE500839T1 ATE500839T1 AT03814319T AT03814319T ATE500839T1 AT E500839 T1 ATE500839 T1 AT E500839T1 AT 03814319 T AT03814319 T AT 03814319T AT 03814319 T AT03814319 T AT 03814319T AT E500839 T1 ATE500839 T1 AT E500839T1
- Authority
- AT
- Austria
- Prior art keywords
- compounds
- methods
- fibrocyte differentiation
- wound
- suppressing
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
- G01N33/505—Cells of the immune system involving T-cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/729—Agar; Agarose; Agaropectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/208—IL-12
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/10—Anthelmintics
- A61P33/12—Schistosomicides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US43604602P | 2002-12-23 | 2002-12-23 | |
US43602702P | 2002-12-23 | 2002-12-23 | |
US51577603P | 2003-10-30 | 2003-10-30 | |
US51946703P | 2003-11-12 | 2003-11-12 | |
US52517503P | 2003-11-26 | 2003-11-26 | |
PCT/US2003/040957 WO2004058292A2 (en) | 2002-12-23 | 2003-12-22 | Methods and compositions for suppressing fibrocyte differentiation |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE500839T1 true ATE500839T1 (de) | 2011-03-15 |
Family
ID=32686361
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT03814319T ATE500839T1 (de) | 2002-12-23 | 2003-12-22 | Verfahren und verbindungen zur unterdrückung der fibrocyten-differenzierung |
AT03800146T ATE422943T1 (de) | 2002-12-23 | 2003-12-22 | Verfahren und verbindungen zur verstärkung der fybrozyten-bildung |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT03800146T ATE422943T1 (de) | 2002-12-23 | 2003-12-22 | Verfahren und verbindungen zur verstärkung der fybrozyten-bildung |
Country Status (13)
Country | Link |
---|---|
US (3) | US7935682B2 (de) |
EP (3) | EP1596880B1 (de) |
JP (4) | JP4819364B2 (de) |
AT (2) | ATE500839T1 (de) |
AU (2) | AU2003299873A1 (de) |
CA (2) | CA2509241C (de) |
CY (1) | CY1111536T1 (de) |
DE (2) | DE60336347D1 (de) |
DK (1) | DK1596880T3 (de) |
ES (1) | ES2318195T3 (de) |
IL (1) | IL169258A0 (de) |
PT (1) | PT1596880E (de) |
WO (2) | WO2004058292A2 (de) |
Families Citing this family (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7935682B2 (en) | 2002-12-23 | 2011-05-03 | William Marsh Rice University | Wound healing dressing for enhancing fibrocyte formation |
US20100297074A1 (en) * | 2002-12-23 | 2010-11-25 | Richard Hans Gomer | Wound healing compositions, systems, and methods |
US8012472B2 (en) | 2002-12-23 | 2011-09-06 | William Marsh Rice University | Compositions and methods for suppressing fibrocytes |
WO2007094776A1 (en) * | 2006-02-15 | 2007-08-23 | William Marsh Rice University | Compositions and methods for suppressing fibrocyte differentiation |
US7763256B2 (en) | 2002-12-23 | 2010-07-27 | William Marsh Rice University | Compositions and methods for suppressing fibrocytes and for detecting fibrocyte differentiation |
US20060264367A1 (en) * | 2005-05-21 | 2006-11-23 | Howard Florey Institute | Prevention of fibrosis following cardiac injury |
US8795668B2 (en) * | 2005-12-23 | 2014-08-05 | The Regents Of The University Of Michigan | Methods for treating pulmonary fibrosis |
US8642307B2 (en) * | 2006-05-25 | 2014-02-04 | Nalge Nunc International Corporation | Cell culture surface chemistries |
FR2902799B1 (fr) | 2006-06-27 | 2012-10-26 | Millipore Corp | Procede et unite de preparation d'un echantillon pour l'analyse microbiologique d'un liquide |
US8114608B2 (en) * | 2006-11-30 | 2012-02-14 | University Of Virginia Patent Foundation | Methods for treating and diagnosing fibrotic and fibroproliferative diseases |
ES2409756T3 (es) * | 2006-12-04 | 2013-06-27 | Promedior, Inc. | Combinación de SAP y de enalapril para su uso en tratamiento de trastornos fibróticos o fibroproliferativos |
US8362217B2 (en) | 2006-12-21 | 2013-01-29 | Emd Millipore Corporation | Purification of proteins |
US8569464B2 (en) | 2006-12-21 | 2013-10-29 | Emd Millipore Corporation | Purification of proteins |
WO2008079280A1 (en) | 2006-12-21 | 2008-07-03 | Millipore Corporation | Purification of proteins |
GB0712503D0 (en) * | 2007-06-27 | 2007-08-08 | Therapeutics Pentraxin Ltd | Use |
US9884899B2 (en) | 2007-07-06 | 2018-02-06 | Promedior, Inc. | Methods for treating fibrosis using CRP antagonists |
US8497243B2 (en) | 2007-07-06 | 2013-07-30 | Promedior, Inc. | Methods and compositions useful in the treatment of mucositis |
AU2008358292B2 (en) * | 2008-06-27 | 2015-05-07 | Pentraxin Therapeutics Limited | Use |
CN105037535A (zh) * | 2008-12-16 | 2015-11-11 | Emd密理博公司 | 搅拌槽反应器及方法 |
PT2405929T (pt) | 2009-03-11 | 2018-07-23 | Promedior Inc | Métodos de tratamento para distúrbios autoimunes |
AU2010224170B2 (en) | 2009-03-11 | 2015-12-24 | Promedior, Inc. | Treatment and diagnostic methods for hypersensitive disorders |
AU2010232591A1 (en) * | 2009-04-01 | 2011-11-03 | Promedior, Inc. | Pulmonary and nasal delivery of serum amyloid P |
UA110323C2 (en) * | 2009-06-04 | 2015-12-25 | Promedior Inc | Derivative of serum amyloid p and their receipt and application |
DK2443144T3 (en) * | 2009-06-17 | 2015-11-23 | Promedior Inc | SAP variants and their application |
UA108227C2 (xx) | 2010-03-03 | 2015-04-10 | Антигензв'язуючий білок | |
US9434716B2 (en) | 2011-03-01 | 2016-09-06 | Glaxo Group Limited | Antigen binding proteins |
EP2571903B1 (de) | 2010-05-17 | 2019-09-04 | EMD Millipore Corporation | Stimulusreaktive polymere zur aufreinigung von biomolekülen |
US8465413B2 (en) | 2010-11-25 | 2013-06-18 | Coloplast A/S | Method of treating Peyronie's disease |
EP2790690A4 (de) * | 2011-12-14 | 2015-08-12 | Texas A & M Univ Sys | Zusammensetzungen und verfahren zur verwaltung neutrophiler bewegungen unter verwendung des serum-amyloids p (sap) |
EP2793927B1 (de) * | 2011-12-21 | 2019-03-06 | Promedior, Inc. | Serum-amyloid-p-antikörper-fusionsproteine |
WO2014112125A1 (ja) * | 2013-01-21 | 2014-07-24 | 三菱電機株式会社 | 電気機器識別システム、電気機器、及び、電気機器識別方法 |
EP2968556A1 (de) * | 2013-03-13 | 2016-01-20 | University Of Kentucky Research Foundation | Verfahren zur verabreichung von igg1-antikörpern und verfahren zur unterdrückung von angiogenese |
JP6601707B2 (ja) * | 2015-02-15 | 2019-11-06 | 国立大学法人金沢大学 | 線維化判定方法 |
EP3413881B1 (de) * | 2016-02-08 | 2021-06-30 | Hackensack University Medical Center | Zusammensetzungen und verfahren zur behandlung von chronischen wunden |
JP6780600B2 (ja) * | 2017-07-28 | 2020-11-04 | 株式会社デンソー | 内燃機関制御システム |
Family Cites Families (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1562244A (en) * | 1976-11-11 | 1980-03-05 | Lock P M | Wound dressing materials |
DE2725261C2 (de) | 1977-06-03 | 1986-10-09 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V., 3400 Göttingen | Transparentes Flüssigkeitsverbandmaterial, seine Herstellung und Verwendung |
GB1594389A (en) * | 1977-06-03 | 1981-07-30 | Max Planck Gesellschaft | Dressing material for wounds |
GB8516081D0 (en) * | 1985-06-25 | 1985-07-31 | Ciba Geigy Ag | Assay & purification of amyloid components |
EP0476721B1 (de) * | 1987-11-20 | 1995-03-01 | Kanegafuchi Kagaku Kogyo Kabushiki Kaisha | Methode zur Entfernung von Serum-Amyloid-Protein |
US7070994B2 (en) * | 1988-03-21 | 2006-07-04 | Oxford Biomedica (Uk) Ltd. | Packaging cells |
US5092876A (en) * | 1989-08-30 | 1992-03-03 | The United States Of America As Represented By The Department Of Health And Human Services | Cell attachment peptides derived from amyloid P component |
US5591709A (en) * | 1991-08-30 | 1997-01-07 | Life Medical Sciences, Inc. | Compositions and methods for treating wounds |
US6054121A (en) * | 1993-02-26 | 2000-04-25 | The Picower Institute For Medical Research | Modulation of immune responses in blood-borne mesenchymal cells |
US5804446A (en) * | 1993-02-26 | 1998-09-08 | The Picower Institute For Medical Research | Blood-borne mesenchymal cells |
US5654186A (en) * | 1993-02-26 | 1997-08-05 | The Picower Institute For Medical Research | Blood-borne mesenchymal cells |
US5698589A (en) * | 1993-06-01 | 1997-12-16 | International Medical Innovations, Inc. | Water-based topical cream containing nitroglycerin and method of preparation and use thereof |
GB9317120D0 (en) * | 1993-08-17 | 1993-09-29 | Royal Postgrad Med School | Human serum amyloid p component |
WO1997026906A1 (en) * | 1996-01-25 | 1997-07-31 | Svehag Sven Erik | Pharmaceutical composition comprising serum amyloid p component for prophylactic or therapeutic treatment of virus infections and a kit for detecting binding of compositions to virus components |
US6365570B1 (en) * | 1997-10-10 | 2002-04-02 | Universiteit Utrecht | Pharmaceutical and diagnostic use of Serum Amyloid P component |
HUP0100929A3 (en) | 1998-02-17 | 2005-10-28 | Celldex Therapeutics Inc | Treating and diagnosing macrophage-mediated diseases using fc receptor ligands |
EP1090630A4 (de) | 1998-03-11 | 2004-06-16 | Soken Kk | Hautnormalisierungsmittel |
JPH11319542A (ja) | 1998-05-08 | 1999-11-24 | Tokuyama Corp | 超薄層の製造方法 |
US6600019B2 (en) * | 2000-01-06 | 2003-07-29 | Curagen Corporation | Polypeptides and nucleic acids encoding same |
WO2001074300A1 (en) | 2000-03-30 | 2001-10-11 | Brennen Medical, Inc. | Anti-microbial and immunostimulating composition |
US20040068095A1 (en) * | 2001-03-14 | 2004-04-08 | Shimkets Richard A. | Novel human proteins, polynucleotides encoding them and methods of using the same |
WO2002098278A2 (en) * | 2001-06-04 | 2002-12-12 | Cytokine Pharmasciences, Inc | Peripheral blood fibrocytes differentiation pathway and migration to wound sites |
US6872541B2 (en) * | 2001-07-25 | 2005-03-29 | Coulter International Corp. | Method and compositions for analysis of pentraxin receptors as indicators of disease |
US6537811B1 (en) * | 2001-08-01 | 2003-03-25 | Isis Pharmaceuticals, Inc. | Antisense inhibition of SAP-1 expression |
US20030199442A1 (en) | 2001-10-09 | 2003-10-23 | Alsobrook John P. | Therapeutic polypeptides, nucleic acids encoding same, and methods of use |
GB0211136D0 (en) | 2002-05-15 | 2002-06-26 | Univ London | Treatment and prevention of tissue damage |
EP1534335B9 (de) | 2002-08-14 | 2016-01-13 | Macrogenics, Inc. | Fcgammariib-spezifische antikörper und verfahren zur verwendung davon |
US7935682B2 (en) * | 2002-12-23 | 2011-05-03 | William Marsh Rice University | Wound healing dressing for enhancing fibrocyte formation |
MXPA06011796A (es) | 2004-04-16 | 2007-05-07 | Macrogenics Inc | Anticuerpos especificos de fc(riib y metodos para el uso de los mismos. |
AU2005244058B2 (en) | 2004-05-10 | 2011-07-28 | Macrogenics, Inc. | Humanized FcgammaRIIB specific antibodies and methods of use thereof |
CA2568661A1 (en) | 2004-06-03 | 2006-01-05 | Medarex, Inc. | Human monoclonal antibodies to fc gamma receptor i (cd64) |
-
2003
- 2003-12-22 US US11/158,723 patent/US7935682B2/en active Active
- 2003-12-22 EP EP03814319A patent/EP1596880B1/de not_active Expired - Lifetime
- 2003-12-22 PT PT03814319T patent/PT1596880E/pt unknown
- 2003-12-22 AT AT03814319T patent/ATE500839T1/de active
- 2003-12-22 JP JP2004564024A patent/JP4819364B2/ja not_active Expired - Fee Related
- 2003-12-22 WO PCT/US2003/040957 patent/WO2004058292A2/en active Application Filing
- 2003-12-22 AU AU2003299873A patent/AU2003299873A1/en not_active Abandoned
- 2003-12-22 CA CA2509241A patent/CA2509241C/en not_active Expired - Lifetime
- 2003-12-22 JP JP2004563958A patent/JP4922560B2/ja not_active Expired - Lifetime
- 2003-12-22 EP EP03800146A patent/EP1576368B1/de not_active Expired - Lifetime
- 2003-12-22 DE DE60336347T patent/DE60336347D1/de not_active Expired - Lifetime
- 2003-12-22 DK DK03814319.4T patent/DK1596880T3/da active
- 2003-12-22 CA CA002509392A patent/CA2509392A1/en not_active Abandoned
- 2003-12-22 WO PCT/US2003/041183 patent/WO2004059318A2/en active Application Filing
- 2003-12-22 AT AT03800146T patent/ATE422943T1/de not_active IP Right Cessation
- 2003-12-22 AU AU2003300266A patent/AU2003300266B2/en not_active Expired
- 2003-12-22 ES ES03800146T patent/ES2318195T3/es not_active Expired - Lifetime
- 2003-12-22 DE DE60326273T patent/DE60326273D1/de not_active Expired - Lifetime
- 2003-12-22 EP EP08165673A patent/EP2017617A1/de not_active Withdrawn
-
2005
- 2005-06-17 IL IL169258A patent/IL169258A0/en unknown
- 2005-06-22 US US11/158,966 patent/US7666432B2/en active Active
-
2010
- 2010-09-02 JP JP2010196332A patent/JP2011016824A/ja active Pending
-
2011
- 2011-06-08 CY CY20111100544T patent/CY1111536T1/el unknown
- 2011-09-02 US US13/224,959 patent/US8187599B2/en not_active Expired - Lifetime
-
2014
- 2014-03-24 JP JP2014059598A patent/JP2014141512A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE500839T1 (de) | Verfahren und verbindungen zur unterdrückung der fibrocyten-differenzierung | |
ATE497778T1 (de) | Lactoferrin-zusammensetzungen und verfahren zur behandlung von diabetischen ulcus | |
ATE409037T1 (de) | Verfahren zur erhöhung der leptinspiegel unter verwendung von nikotinsäureverbindungen | |
ATE345130T1 (de) | Arylharnstoff-verbindungen in kombination mit anderen zytostatisch oder zytotoxisch wirksamen stoffen zur behandlungen menschlicher krebserkrankungen | |
ATE550005T1 (de) | Integriertes wundverbandsystem | |
DE602004023829D1 (de) | Verfahren zur behandlung von sinuskopfschmerzen | |
TW200714283A (en) | Method and composition for treating peripheral vascular diseases | |
DE602006015695D1 (de) | Oxidationsinhibierung von kohlenstoff-kohlenstoff-verbundwerkstoffen | |
WO2005046618A3 (en) | Methods of treating eczema | |
AU2002361878A1 (en) | Method of improving wound healing | |
BRPI0509363A (pt) | método para aumentar a eficácia preservativa de uma composição, composição oftálmica, método de tratamento de uma condição oftálmica e processo para produzir uma composição oftálmica | |
DE60229406D1 (de) | Verfahren zur behandlung oder verhinderung von vaskulärer entzündung mit sterol-absorbierungs- inhibitor(en) | |
ATE495735T1 (de) | Verfahren und zusammensetzung, die immunomodulatorische verbindungen zur behandlung von mit niedrigen plasmaleptin-spiegeln in zusammenhang stehenden störungen verwenden | |
ATE444749T1 (de) | Benzothiazolium verbindungen zur verwendung in methoden zur hemmung der no produktion und von tnf alpha und zur behandlung von coronavirus infektionen | |
ATE346614T1 (de) | Vaginale zusammensetzung enthaltend lidocaine zur behandlung von gebärmutterrhythmusstörung | |
DE60114439D1 (de) | Verfahren zur antimikrobiellen behandlung von fasermaterialien | |
DE60220043D1 (de) | Carbamatverbindungen zur vorbeugung oder behandlung von neurodegenerativen störungen | |
DE60313434D1 (de) | Verfahren und zusammensetzungen zur behandlung von hyperproliferativen zuständen | |
AR040303A1 (es) | Vendaje para heridas que contiene un polisacarido regenerado modificado con aldehido | |
WO2002089730A3 (en) | Compounds and methods for the modulation of cd154 | |
DE602006015373D1 (de) | Zusammensetzungen und Verfahren zur Prävention und Behandlung von immunvermittelten Entzündungskrankheiten | |
ATE278441T1 (de) | Verfahren zum auffinden von verbindungen, welche zur behandlung und/oder prophylaxe von obesitas geeignet sind | |
ATE376419T1 (de) | Carbostyril-derivate mit selektiven serotonin- aufnahme inhibitoren, zur behandlung von gemütskrankheiten | |
ATE431741T1 (de) | Marrubin und zusammensetzung zur verringerung von schnarchen, verpackung und verfahren | |
DE602007010459D1 (de) | Verwendung von Verbindungen, die die EF-Tu-Nucleolin Wechselwirkung vehindern, zur Verhinderung oder Behandlung von Tularämie |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
UEP | Publication of translation of european patent specification |
Ref document number: 1596880 Country of ref document: EP |